290 related articles for article (PubMed ID: 30252101)
1. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.
Korshunov A; Sahm F; Zheludkova O; Golanov A; Stichel D; Schrimpf D; Ryzhova M; Potapov A; Habel A; Meyer J; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
Neuro Oncol; 2019 Feb; 21(2):214-221. PubMed ID: 30252101
[TBL] [Abstract][Full Text] [Related]
2. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
3. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
4. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
[TBL] [Abstract][Full Text] [Related]
5. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
Clifford SC; Lusher ME; Lindsey JC; Langdon JA; Gilbertson RJ; Straughton D; Ellison DW
Cell Cycle; 2006 Nov; 5(22):2666-70. PubMed ID: 17172831
[TBL] [Abstract][Full Text] [Related]
6. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
[No Abstract] [Full Text] [Related]
7. Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P
Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Ror2 and Wnt5a expression in medulloblastoma.
Lee SE; Lim SD; Kang SY; Suh SB; Suh YL
Brain Pathol; 2013 Jul; 23(4):445-53. PubMed ID: 23278988
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
[TBL] [Abstract][Full Text] [Related]
10. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
[TBL] [Abstract][Full Text] [Related]
11. Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours.
Goschzik T; Zur Mühlen A; Kristiansen G; Haberler C; Stefanits H; Friedrich C; von Hoff K; Rutkowski S; Pfister SM; Pietsch T
Neuropathol Appl Neurobiol; 2015 Feb; 41(2):135-44. PubMed ID: 24894640
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of ALK protein identifies APC mutated medulloblastoma and differentiates the WNT-activated medulloblastoma from other types of posterior fossa childhood tumors.
Łastowska M; Trubicka J; Karkucińska-Więckowska A; Kaleta M; Tarasińska M; Perek-Polnik M; Sobocińska AA; Dembowska-Bagińska B; Grajkowska W; Matyja E
Brain Tumor Pathol; 2019 Jan; 36(1):1-6. PubMed ID: 30523493
[TBL] [Abstract][Full Text] [Related]
13. Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma.
Li Y; Jiang T; Shao L; Liu Y; Zheng C; Zhong Y; Zhang J; Chang Q
J Neurooncol; 2016 Sep; 129(3):423-431. PubMed ID: 27406588
[TBL] [Abstract][Full Text] [Related]
14. Rapid diagnosis of medulloblastoma molecular subgroups.
Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Accuracy of a Reduced Immunohistochemical Panel in Medulloblastoma Molecular Subtyping, Correlated to DNA-methylation Analysis.
Tauziède-Espariat A; Huybrechts S; Indersie E; Dufour C; Puget S; Chivet A; Roux A; Pagès M; Gareton A; Chrétien F; Lechapt E; Ayrault O; Varlet P
Am J Surg Pathol; 2021 Apr; 45(4):558-566. PubMed ID: 33323893
[TBL] [Abstract][Full Text] [Related]
16. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
[TBL] [Abstract][Full Text] [Related]
17. A simplified approach using Taqman low-density array for medulloblastoma subgrouping.
Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET
Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734
[TBL] [Abstract][Full Text] [Related]
18. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
Goschzik T; Zur Muehlen A; Doerner E; Waha A; Friedrich C; Hau P; Pietsch T
J Neuropathol Exp Neurol; 2021 Apr; 80(5):419-430. PubMed ID: 33870422
[TBL] [Abstract][Full Text] [Related]
19. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
[TBL] [Abstract][Full Text] [Related]
20. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
